Short dual antiplatelet therapy duration after percutaneous coronary intervention in high bleeding risk patients: Systematic review and meta-analysis

Dual antiplatelet therapy (DAPT) following percutaneous coronary intervention (PCI) reduces major adverse cardiovascular events (MACE) and stent thrombosis. However, DAPT duration is a concern in high bleeding risk (HBR) patients. We evaluated the effect of short DAPT (1-3 months) compared to standa...

Celý popis

Uloženo v:

Podrobná bibliografie
Vydáno v:	PloS one Ročník 18; číslo 9; s. e0291061
Hlavní autoři:	Bainey, Kevin R., Marquis-Gravel, Guillaume, MacDonald, Blair J., Bewick, David, Yan, Andrew, Turgeon, Ricky D.
Médium:	Journal Article
Jazyk:	angličtina
Vydáno:	San Francisco Public Library of Science 01.09.2023 Public Library of Science (PLoS)
Témata:	Acute coronary syndromes Aggregation Angioplasty Anticoagulants Antiplatelet therapy Bias Bleeding Blood clot Blood platelets Cardiovascular diseases Care and treatment Clinical trials Confidence intervals Consortia Health risks Heart attacks Implants Intervention Ischemia Medicine and Health Sciences Meta-analysis Mortality Patient outcomes Physical Sciences Prevention Research and Analysis Methods Risk assessment Stents Systematic review Thromboembolism Thrombosis Canada
ISSN:	1932-6203, 1932-6203
On-line přístup:	Získat plný text
Tagy:	Přidat tag Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!

Abstract	Dual antiplatelet therapy (DAPT) following percutaneous coronary intervention (PCI) reduces major adverse cardiovascular events (MACE) and stent thrombosis. However, DAPT duration is a concern in high bleeding risk (HBR) patients. We evaluated the effect of short DAPT (1-3 months) compared to standard DAPT (6-12 months) on bleeding and ischemic events in HBR PCI. We searched MEDLINE, Embase and CENTRAL up to August 18, 2022. Randomized controlled trials (RCTs) comparing short DAPT (1-3 months) versus standard DAPT in HBR PCI were included. We assessed risk of bias (RoB) using the Cochrane RoB2 tool, and certainty of evidence using GRADE criteria. Outcomes included MACE, all-cause death, stent thrombosis, major bleeding, and the composite of major or clinically-relevant non-major bleeding. We estimated risk ratios (RR) and 95% confidence intervals (CI) using a random-effects model. From 503 articles, we included five RCTs (n = 7,242) at overall low risk of bias with median follow-up of 12-months. Compared to standard DAPT, short DAPT did not increase MACE (RR 1.02, 95% CI 0.84-1.23), all-cause death (RR 0.92, 95% CI 0.71-1.20) or stent thrombosis (RR 1.47, 95% CI 0.73-2.93). Short DAPT reduced major bleeding (RR 0.34, 95% CI 0.13-0.90) and the composite of major or clinically-relevant non-major bleeding (RR 0.60, 95% CI 0.44-0.81), translating to 21 and 34 fewer events, respectively, per 1000 patients. In HBR PCI, DAPT for 1-3 months compared to 6-12 months reduced clinically-relevant bleeding events without jeopardizing ischemic risk. Short DAPT should be considered in HBR patients receiving PCI.
AbstractList	Introduction Dual antiplatelet therapy (DAPT) following percutaneous coronary intervention (PCI) reduces major adverse cardiovascular events (MACE) and stent thrombosis. However, DAPT duration is a concern in high bleeding risk (HBR) patients. We evaluated the effect of short DAPT (1-3 months) compared to standard DAPT (6-12 months) on bleeding and ischemic events in HBR PCI. Methods We searched MEDLINE, Embase and CENTRAL up to August 18, 2022. Randomized controlled trials (RCTs) comparing short DAPT (1-3 months) versus standard DAPT in HBR PCI were included. We assessed risk of bias (RoB) using the Cochrane RoB2 tool, and certainty of evidence using GRADE criteria. Outcomes included MACE, all-cause death, stent thrombosis, major bleeding, and the composite of major or clinically-relevant non-major bleeding. We estimated risk ratios (RR) and 95% confidence intervals (CI) using a random-effects model. Results From 503 articles, we included five RCTs (n = 7,242) at overall low risk of bias with median follow-up of 12-months. Compared to standard DAPT, short DAPT did not increase MACE (RR 1.02, 95% CI 0.84-1.23), all-cause death (RR 0.92, 95% CI 0.71-1.20) or stent thrombosis (RR 1.47, 95% CI 0.73-2.93). Short DAPT reduced major bleeding (RR 0.34, 95% CI 0.13-0.90) and the composite of major or clinically-relevant non-major bleeding (RR 0.60, 95% CI 0.44-0.81), translating to 21 and 34 fewer events, respectively, per 1000 patients. Conclusions In HBR PCI, DAPT for 1-3 months compared to 6-12 months reduced clinically-relevant bleeding events without jeopardizing ischemic risk. Short DAPT should be considered in HBR patients receiving PCI. Dual antiplatelet therapy (DAPT) following percutaneous coronary intervention (PCI) reduces major adverse cardiovascular events (MACE) and stent thrombosis. However, DAPT duration is a concern in high bleeding risk (HBR) patients. We evaluated the effect of short DAPT (1-3 months) compared to standard DAPT (6-12 months) on bleeding and ischemic events in HBR PCI. We searched MEDLINE, Embase and CENTRAL up to August 18, 2022. Randomized controlled trials (RCTs) comparing short DAPT (1-3 months) versus standard DAPT in HBR PCI were included. We assessed risk of bias (RoB) using the Cochrane RoB2 tool, and certainty of evidence using GRADE criteria. Outcomes included MACE, all-cause death, stent thrombosis, major bleeding, and the composite of major or clinically-relevant non-major bleeding. We estimated risk ratios (RR) and 95% confidence intervals (CI) using a random-effects model. From 503 articles, we included five RCTs (n = 7,242) at overall low risk of bias with median follow-up of 12-months. Compared to standard DAPT, short DAPT did not increase MACE (RR 1.02, 95% CI 0.84-1.23), all-cause death (RR 0.92, 95% CI 0.71-1.20) or stent thrombosis (RR 1.47, 95% CI 0.73-2.93). Short DAPT reduced major bleeding (RR 0.34, 95% CI 0.13-0.90) and the composite of major or clinically-relevant non-major bleeding (RR 0.60, 95% CI 0.44-0.81), translating to 21 and 34 fewer events, respectively, per 1000 patients. In HBR PCI, DAPT for 1-3 months compared to 6-12 months reduced clinically-relevant bleeding events without jeopardizing ischemic risk. Short DAPT should be considered in HBR patients receiving PCI. Dual antiplatelet therapy (DAPT) following percutaneous coronary intervention (PCI) reduces major adverse cardiovascular events (MACE) and stent thrombosis. However, DAPT duration is a concern in high bleeding risk (HBR) patients. We evaluated the effect of short DAPT (1-3 months) compared to standard DAPT (6-12 months) on bleeding and ischemic events in HBR PCI.INTRODUCTIONDual antiplatelet therapy (DAPT) following percutaneous coronary intervention (PCI) reduces major adverse cardiovascular events (MACE) and stent thrombosis. However, DAPT duration is a concern in high bleeding risk (HBR) patients. We evaluated the effect of short DAPT (1-3 months) compared to standard DAPT (6-12 months) on bleeding and ischemic events in HBR PCI.We searched MEDLINE, Embase and CENTRAL up to August 18, 2022. Randomized controlled trials (RCTs) comparing short DAPT (1-3 months) versus standard DAPT in HBR PCI were included. We assessed risk of bias (RoB) using the Cochrane RoB2 tool, and certainty of evidence using GRADE criteria. Outcomes included MACE, all-cause death, stent thrombosis, major bleeding, and the composite of major or clinically-relevant non-major bleeding. We estimated risk ratios (RR) and 95% confidence intervals (CI) using a random-effects model.METHODSWe searched MEDLINE, Embase and CENTRAL up to August 18, 2022. Randomized controlled trials (RCTs) comparing short DAPT (1-3 months) versus standard DAPT in HBR PCI were included. We assessed risk of bias (RoB) using the Cochrane RoB2 tool, and certainty of evidence using GRADE criteria. Outcomes included MACE, all-cause death, stent thrombosis, major bleeding, and the composite of major or clinically-relevant non-major bleeding. We estimated risk ratios (RR) and 95% confidence intervals (CI) using a random-effects model.From 503 articles, we included five RCTs (n = 7,242) at overall low risk of bias with median follow-up of 12-months. Compared to standard DAPT, short DAPT did not increase MACE (RR 1.02, 95% CI 0.84-1.23), all-cause death (RR 0.92, 95% CI 0.71-1.20) or stent thrombosis (RR 1.47, 95% CI 0.73-2.93). Short DAPT reduced major bleeding (RR 0.34, 95% CI 0.13-0.90) and the composite of major or clinically-relevant non-major bleeding (RR 0.60, 95% CI 0.44-0.81), translating to 21 and 34 fewer events, respectively, per 1000 patients.RESULTSFrom 503 articles, we included five RCTs (n = 7,242) at overall low risk of bias with median follow-up of 12-months. Compared to standard DAPT, short DAPT did not increase MACE (RR 1.02, 95% CI 0.84-1.23), all-cause death (RR 0.92, 95% CI 0.71-1.20) or stent thrombosis (RR 1.47, 95% CI 0.73-2.93). Short DAPT reduced major bleeding (RR 0.34, 95% CI 0.13-0.90) and the composite of major or clinically-relevant non-major bleeding (RR 0.60, 95% CI 0.44-0.81), translating to 21 and 34 fewer events, respectively, per 1000 patients.In HBR PCI, DAPT for 1-3 months compared to 6-12 months reduced clinically-relevant bleeding events without jeopardizing ischemic risk. Short DAPT should be considered in HBR patients receiving PCI.CONCLUSIONSIn HBR PCI, DAPT for 1-3 months compared to 6-12 months reduced clinically-relevant bleeding events without jeopardizing ischemic risk. Short DAPT should be considered in HBR patients receiving PCI. Introduction Dual antiplatelet therapy (DAPT) following percutaneous coronary intervention (PCI) reduces major adverse cardiovascular events (MACE) and stent thrombosis. However, DAPT duration is a concern in high bleeding risk (HBR) patients. We evaluated the effect of short DAPT (1–3 months) compared to standard DAPT (6–12 months) on bleeding and ischemic events in HBR PCI. Methods We searched MEDLINE, Embase and CENTRAL up to August 18, 2022. Randomized controlled trials (RCTs) comparing short DAPT (1–3 months) versus standard DAPT in HBR PCI were included. We assessed risk of bias (RoB) using the Cochrane RoB2 tool, and certainty of evidence using GRADE criteria. Outcomes included MACE, all-cause death, stent thrombosis, major bleeding, and the composite of major or clinically-relevant non-major bleeding. We estimated risk ratios (RR) and 95% confidence intervals (CI) using a random-effects model. Results From 503 articles, we included five RCTs (n = 7,242) at overall low risk of bias with median follow-up of 12-months. Compared to standard DAPT, short DAPT did not increase MACE (RR 1.02, 95% CI 0.84–1.23), all-cause death (RR 0.92, 95% CI 0.71–1.20) or stent thrombosis (RR 1.47, 95% CI 0.73–2.93). Short DAPT reduced major bleeding (RR 0.34, 95% CI 0.13–0.90) and the composite of major or clinically-relevant non-major bleeding (RR 0.60, 95% CI 0.44–0.81), translating to 21 and 34 fewer events, respectively, per 1000 patients. Conclusions In HBR PCI, DAPT for 1–3 months compared to 6–12 months reduced clinically-relevant bleeding events without jeopardizing ischemic risk. Short DAPT should be considered in HBR patients receiving PCI.
Audience	Academic
Author	Bewick, David Marquis-Gravel, Guillaume Bainey, Kevin R. MacDonald, Blair J. Yan, Andrew Turgeon, Ricky D.
AuthorAffiliation	1 Mazankowski Alberta Heart Institute, University of Alberta, Edmonton, Alberta Baylor Scott and White, Texas A&M College of Medicine, UNITED STATES 3 Faculty of Pharmaceutical Sciences, University of British Columbia, Vancouver, British Columbia 2 Montreal Heart Institute, Université de Montréal, Montreal, Quebec 5 Division of Cardiology, Canadian Heart Research Centre and Terrence Donnelly Heart Centre, St Michael’s Hospital, University of Toronto, Toronto, Ontario 4 New Brunswick Heart Center, Horizon Health Network, Saint John, New Brunswick
AuthorAffiliation_xml	– name: 2 Montreal Heart Institute, Université de Montréal, Montreal, Quebec – name: Baylor Scott and White, Texas A&M College of Medicine, UNITED STATES – name: 5 Division of Cardiology, Canadian Heart Research Centre and Terrence Donnelly Heart Centre, St Michael’s Hospital, University of Toronto, Toronto, Ontario – name: 3 Faculty of Pharmaceutical Sciences, University of British Columbia, Vancouver, British Columbia – name: 4 New Brunswick Heart Center, Horizon Health Network, Saint John, New Brunswick – name: 1 Mazankowski Alberta Heart Institute, University of Alberta, Edmonton, Alberta
Author_xml	– sequence: 1 givenname: Kevin R. surname: Bainey fullname: Bainey, Kevin R. – sequence: 2 givenname: Guillaume surname: Marquis-Gravel fullname: Marquis-Gravel, Guillaume – sequence: 3 givenname: Blair J. orcidid: 0000-0002-4666-1790 surname: MacDonald fullname: MacDonald, Blair J. – sequence: 4 givenname: David surname: Bewick fullname: Bewick, David – sequence: 5 givenname: Andrew surname: Yan fullname: Yan, Andrew – sequence: 6 givenname: Ricky D. orcidid: 0000-0002-3967-1528 surname: Turgeon fullname: Turgeon, Ricky D.
BookMark	eNqNk9tq3DAQhk1JoUnaNyhUUCjtxW4l2_IhNyWEHgKBQNP2Vozt8VqpVnIkOe0-SN-3s4dANoRSfGF75pt_DtIcJQfWWUySl4LPRVaK99du8hbMfCTznKe14IV4khyKOktnRcqzg3vfz5KjEK45l1lVFIfJn6vB-ci6CQwDG_VoIKLByOKAHsYVeTxE7SyDPqJnI_p2imDRTYG1zjsLfsW0Jd8t2g2oLRv0YmCNQey0XTCvw082kgoB4YRdrULEJf22zOOtxl-UuGNLjDAD6mIVdHiePO3BBHyxex8n3z99_Hb2ZXZx-fn87PRi1hYlj7O27_MmlQjYtbKHWoq-6bgQXVenkMpOFIKnWFS8Kuq-b0QqJciyBGiJQGiy4-TVVnc0LqjdGINKK1nXJZdlTcT5lugcXKvR6yX1qxxotTE4v1DgqRWDKi-6ErI8hxbrnOYNKTSiaXIps7rBAkjrwy7b1CypZBqHB7Mnuu-xelALd6sEz8tM8pIU3u4UvLuZMES11KFFY7YHQoUXPOe8yiShrx-gj7e3oxZAHWjbO0rcrkXVaVmkdZXLKidq_ghFT4dL3dKl6zXZ9wLe7QUQE_F3XMAUgjq_-vr_7OWPffbNPXZAMHEIzkzrexf2wZMt2HoXgsdetTpu7jFVrg1NVK03524mar05arc5FJw_CL47on-G_QWHYCT9
CitedBy_id	crossref_primary_10_1016_j_jcin_2024_08_030 crossref_primary_10_1186_s12872_025_04765_x crossref_primary_10_1016_j_jscai_2024_102496 crossref_primary_10_1016_j_rpth_2024_102539 crossref_primary_10_1016_j_cjca_2023_10_013 crossref_primary_10_1016_j_cjca_2023_10_026 crossref_primary_10_1016_j_jcin_2024_09_027
Cites_doi	10.1016/j.jacc.2018.11.048 10.1056/NEJMoa1910021 10.1093/eurheartj/ehac706 10.1016/S0140-6736(18)31858-0 10.1016/S0140-6736(21)01063-1 10.1056/NEJMoa2108749 10.1016/S0140-6736(21)01445-8 10.1093/eurheartj/ehab702 10.1136/bmj.l2222 10.1161/CIRCULATIONAHA.117.029289 10.1016/S0140-6736(20)31791-8 10.1161/CIRCULATIONAHA.106.685313 10.1016/j.jclinepi.2010.07.015 10.1016/j.jacc.2021.08.074 10.1016/j.jacc.2022.04.065 10.1016/j.jacc.2020.05.031 10.1001/jama.2019.8145 10.1016/S0140-6736(96)09457-3 10.1161/CIRCULATIONAHA.119.040167 10.1016/S0140-6736(17)30397-5 10.1001/jama.2019.8146 10.1007/s12928-020-00651-9 10.1093/eurheartj/ehac284 10.1001/jama.2020.7580 10.1001/jamacardio.2021.5244 10.1093/ehjcvp/pvaa001 10.1093/eurheartj/ehx175 10.1161/CIRCULATIONAHA.119.043613 10.1093/ehjcvp/pvaa127 10.1161/CIRCINTERVENTIONS.111.967083 10.1056/NEJMoa1908419
ContentType	Journal Article
Copyright	COPYRIGHT 2023 Public Library of Science 2023 Bainey et al. This is an open access article distributed under the terms of the Creative Commons Attribution License: http://creativecommons.org/licenses/by/4.0/ (the “License”), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. Copyright: © 2023 Bainey et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. 2023 Bainey et al 2023 Bainey et al 2023 Bainey et al. This is an open access article distributed under the terms of the Creative Commons Attribution License: http://creativecommons.org/licenses/by/4.0/ (the “License”), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.
Copyright_xml	– notice: COPYRIGHT 2023 Public Library of Science – notice: 2023 Bainey et al. This is an open access article distributed under the terms of the Creative Commons Attribution License: http://creativecommons.org/licenses/by/4.0/ (the “License”), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. – notice: Copyright: © 2023 Bainey et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. – notice: 2023 Bainey et al 2023 Bainey et al – notice: 2023 Bainey et al. This is an open access article distributed under the terms of the Creative Commons Attribution License: http://creativecommons.org/licenses/by/4.0/ (the “License”), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.
DBID	AAYXX CITATION IOV ISR 3V. 7QG 7QL 7QO 7RV 7SN 7SS 7T5 7TG 7TM 7U9 7X2 7X7 7XB 88E 8AO 8C1 8FD 8FE 8FG 8FH 8FI 8FJ 8FK ABJCF ABUWG AEUYN AFKRA ARAPS ATCPS AZQEC BBNVY BENPR BGLVJ BHPHI C1K CCPQU D1I DWQXO FR3 FYUFA GHDGH GNUQQ H94 HCIFZ K9. KB. KB0 KL. L6V LK8 M0K M0S M1P M7N M7P M7S NAPCQ P5Z P62 P64 PATMY PDBOC PHGZM PHGZT PIMPY PJZUB PKEHL PPXIY PQEST PQGLB PQQKQ PQUKI PRINS PTHSS PYCSY RC3 7X8 5PM DOA
DOI	10.1371/journal.pone.0291061
DatabaseName	CrossRef Gale In Context: Opposing Viewpoints Gale In Context: Science ProQuest Central (Corporate) Animal Behavior Abstracts Bacteriology Abstracts (Microbiology B) Biotechnology Research Abstracts Nursing & Allied Health Database Ecology Abstracts Entomology Abstracts (Full archive) Immunology Abstracts Meteorological & Geoastrophysical Abstracts Nucleic Acids Abstracts Virology and AIDS Abstracts Agricultural Science Collection ProQuest_Health & Medical Collection ProQuest Central (purchase pre-March 2016) Medical Database (Alumni Edition) ProQuest Pharma Collection Public Health Database Technology Research Database ProQuest SciTech Collection ProQuest Technology Collection ProQuest Natural Science Journals Hospital Premium Collection Hospital Premium Collection (Alumni Edition) ProQuest Central (Alumni) (purchase pre-March 2016) ProQuest Materials Science & Engineering ProQuest Central (Alumni) One Sustainability ProQuest Central UK/Ireland Advanced Technologies & Computer Science Collection Agricultural & Environmental Science Collection ProQuest Central Essentials Biological Science Collection AUTh Library subscriptions: ProQuest Central Technology collection Natural Science Collection Environmental Sciences and Pollution Management ProQuest One Community College ProQuest Materials Science Collection ProQuest Central Engineering Research Database Health Research Premium Collection Health Research Premium Collection (Alumni) ProQuest Central Student AIDS and Cancer Research Abstracts SciTech Premium Collection ProQuest Health & Medical Complete (Alumni) Materials Science Database Nursing & Allied Health Database (Alumni Edition) Meteorological & Geoastrophysical Abstracts - Academic ProQuest Engineering Collection Biological Sciences Agricultural Science Database ProQuest Health & Medical Collection PML(ProQuest Medical Library) Algology Mycology and Protozoology Abstracts (Microbiology C) Biological Science Database Engineering Database Nursing & Allied Health Premium Advanced Technologies & Aerospace Database ProQuest Advanced Technologies & Aerospace Collection Biotechnology and BioEngineering Abstracts Environmental Science Database Materials Science Collection (ProQuest) ProQuest Databases ProQuest One Academic Publicly Available Content Database ProQuest Health & Medical Research Collection ProQuest One Academic Middle East (New) One Health & Nursing ProQuest One Academic Eastern Edition (DO NOT USE) One Applied & Life Sciences ProQuest One Academic (retired) ProQuest One Academic UKI Edition ProQuest Central China Engineering Collection (ProQuest) Environmental Science Collection Genetics Abstracts MEDLINE - Academic PubMed Central (Full Participant titles) Open Access: DOAJ - Directory of Open Access Journals
DatabaseTitle	CrossRef Agricultural Science Database Publicly Available Content Database ProQuest Central Student ProQuest Advanced Technologies & Aerospace Collection ProQuest Central Essentials Nucleic Acids Abstracts SciTech Premium Collection ProQuest Central China Environmental Sciences and Pollution Management ProQuest One Applied & Life Sciences ProQuest One Sustainability Health Research Premium Collection Meteorological & Geoastrophysical Abstracts Natural Science Collection Health & Medical Research Collection Biological Science Collection ProQuest Central (New) ProQuest Medical Library (Alumni) Engineering Collection Advanced Technologies & Aerospace Collection Engineering Database Virology and AIDS Abstracts ProQuest Biological Science Collection ProQuest One Academic Eastern Edition Agricultural Science Collection ProQuest Hospital Collection ProQuest Technology Collection Health Research Premium Collection (Alumni) Biological Science Database Ecology Abstracts ProQuest Hospital Collection (Alumni) Biotechnology and BioEngineering Abstracts Environmental Science Collection Entomology Abstracts Nursing & Allied Health Premium ProQuest Health & Medical Complete ProQuest One Academic UKI Edition Environmental Science Database ProQuest Nursing & Allied Health Source (Alumni) Engineering Research Database ProQuest One Academic Meteorological & Geoastrophysical Abstracts - Academic ProQuest One Academic (New) Technology Collection Technology Research Database ProQuest One Academic Middle East (New) Materials Science Collection ProQuest Health & Medical Complete (Alumni) ProQuest Central (Alumni Edition) ProQuest One Community College ProQuest One Health & Nursing ProQuest Natural Science Collection ProQuest Pharma Collection ProQuest Central ProQuest Health & Medical Research Collection Genetics Abstracts ProQuest Engineering Collection Biotechnology Research Abstracts Health and Medicine Complete (Alumni Edition) ProQuest Central Korea Bacteriology Abstracts (Microbiology B) Algology Mycology and Protozoology Abstracts (Microbiology C) Agricultural & Environmental Science Collection AIDS and Cancer Research Abstracts Materials Science Database ProQuest Materials Science Collection ProQuest Public Health ProQuest Nursing & Allied Health Source ProQuest SciTech Collection Advanced Technologies & Aerospace Database ProQuest Medical Library Animal Behavior Abstracts Materials Science & Engineering Collection Immunology Abstracts ProQuest Central (Alumni) MEDLINE - Academic
DatabaseTitleList	Agricultural Science Database MEDLINE - Academic
Database_xml	– sequence: 1 dbid: DOA name: DOAJ Directory of Open Access Journals url: https://www.doaj.org/ sourceTypes: Open Website – sequence: 2 dbid: PIMPY name: Publicly Available Content Database url: http://search.proquest.com/publiccontent sourceTypes: Aggregation Database
DeliveryMethod	fulltext_linktorsrc
Discipline	Sciences (General)
DocumentTitleAlternate	Short DAPT duration after PCI in high bleeding risk patients
EISSN	1932-6203
ExternalDocumentID	2859970579 oai_doaj_org_article_46d7a344ace94193a2ab1bb45539be6a PMC10473507 A762984584 10_1371_journal_pone_0291061
GeographicLocations	Canada
GeographicLocations_xml	– name: Canada
GrantInformation_xml	– fundername: ;
GroupedDBID	--- 123 29O 2WC 53G 5VS 7RV 7X2 7X7 7XC 88E 8AO 8C1 8CJ 8FE 8FG 8FH 8FI 8FJ A8Z AAFWJ AAUCC AAWOE AAYXX ABDBF ABIVO ABJCF ABUWG ACCTH ACGFO ACIHN ACIWK ACPRK ACUHS ADBBV AEAQA AENEX AEUYN AFFHD AFKRA AFPKN AFRAH AHMBA ALMA_UNASSIGNED_HOLDINGS AOIJS APEBS ARAPS ATCPS BAIFH BAWUL BBNVY BBTPI BCNDV BENPR BGLVJ BHPHI BKEYQ BPHCQ BVXVI BWKFM CCPQU CITATION CS3 D1I D1J D1K DIK DU5 E3Z EAP EAS EBD EMOBN ESX EX3 F5P FPL FYUFA GROUPED_DOAJ GX1 HCIFZ HH5 HMCUK HYE IAO IEA IGS IHR IHW INH INR IOV IPY ISE ISR ITC K6- KB. KQ8 L6V LK5 LK8 M0K M1P M48 M7P M7R M7S M~E NAPCQ O5R O5S OK1 OVT P2P P62 PATMY PDBOC PHGZM PHGZT PIMPY PJZUB PPXIY PQGLB PQQKQ PROAC PSQYO PTHSS PV9 PYCSY RNS RPM RZL SV3 TR2 UKHRP WOQ WOW ~02 ~KM ALIPV BBORY 3V. 7QG 7QL 7QO 7SN 7SS 7T5 7TG 7TM 7U9 7XB 8FD 8FK AZQEC C1K DWQXO ESTFP FR3 GNUQQ H94 K9. KL. M7N P64 PKEHL PQEST PQUKI PRINS RC3 7X8 PUEGO 5PM
ID	FETCH-LOGICAL-c670t-cff4b25eaedc5fa951fbd011dd92a25d16102e680869ffb1255a577aacdd9eab3
IEDL.DBID	FPL
ISICitedReferencesCount	6
ISICitedReferencesURI	http://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=Summon&SrcAuth=ProQuest&DestLinkType=CitingArticles&DestApp=WOS_CPL&KeyUT=001066578500007&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D
ISSN	1932-6203
IngestDate	Thu Nov 28 02:59:01 EST 2024 Fri Oct 03 12:53:33 EDT 2025 Tue Nov 04 02:06:08 EST 2025 Thu Oct 02 11:28:44 EDT 2025 Tue Oct 07 07:52:03 EDT 2025 Sat Nov 29 14:11:25 EST 2025 Sat Nov 29 10:53:20 EST 2025 Wed Nov 26 11:34:57 EST 2025 Wed Nov 26 11:26:49 EST 2025 Thu May 22 21:23:27 EDT 2025 Sat Nov 29 03:50:32 EST 2025 Tue Nov 18 21:19:09 EST 2025
IsDoiOpenAccess	true
IsOpenAccess	true
IsPeerReviewed	true
IsScholarly	true
Issue	9
Language	English
License	This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. Creative Commons Attribution License
LinkModel	DirectLink
MergedId	FETCHMERGED-LOGICAL-c670t-cff4b25eaedc5fa951fbd011dd92a25d16102e680869ffb1255a577aacdd9eab3
Notes	ObjectType-Article-2 SourceType-Scholarly Journals-1 content type line 14 ObjectType-Feature-3 ObjectType-Evidence Based Healthcare-1 ObjectType-Feature-1 content type line 23 ObjectType-Undefined-3 Competing Interests: The authors have declared that no competing interests exist.
ORCID	0000-0002-4666-1790 0000-0002-3967-1528
OpenAccessLink	http://dx.doi.org/10.1371/journal.pone.0291061
PQID	2859970579
PQPubID	1436336
PageCount	e0291061
ParticipantIDs	plos_journals_2859970579 doaj_primary_oai_doaj_org_article_46d7a344ace94193a2ab1bb45539be6a pubmedcentral_primary_oai_pubmedcentral_nih_gov_10473507 proquest_miscellaneous_2860400835 proquest_journals_2859970579 gale_infotracmisc_A762984584 gale_infotracacademiconefile_A762984584 gale_incontextgauss_ISR_A762984584 gale_incontextgauss_IOV_A762984584 gale_healthsolutions_A762984584 crossref_citationtrail_10_1371_journal_pone_0291061 crossref_primary_10_1371_journal_pone_0291061
PublicationCentury	2000
PublicationDate	2023-09-01
PublicationDateYYYYMMDD	2023-09-01
PublicationDate_xml	– month: 09 year: 2023 text: 2023-09-01 day: 01
PublicationDecade	2020
PublicationPlace	San Francisco
PublicationPlace_xml	– name: San Francisco – name: San Francisco, CA USA
PublicationTitle	PloS one
PublicationYear	2023
Publisher	Public Library of Science Public Library of Science (PLoS)
Publisher_xml	– name: Public Library of Science – name: Public Library of Science (PLoS)
References	CJ Kim (pone.0291061.ref037) 2021; 398 P Urban (pone.0291061.ref013) 2019; 140 G Marquis-Gravel (pone.0291061.ref011) 2020; 76 H Watanabe (pone.0291061.ref026) 2021; 36 SR Mehta (pone.0291061.ref001) 2018 BK Kim (pone.0291061.ref008) 2020; 323 DE Cutlip (pone.0291061.ref016) 2007; 115 Y Obayashi (pone.0291061.ref027) 2022; 15 S-H-L Yin (pone.0291061.ref029) 2019; 365 J Escaned (pone.0291061.ref023) 2021; 42 H Watanabe (pone.0291061.ref025) 2019; 140 H Watanabe (pone.0291061.ref009) 2022; 7 M. Gent (pone.0291061.ref035) 1996; 348 M Valgimigli (pone.0291061.ref019) 2021; 385 H Balshem (pone.0291061.ref015) 2011; 64 M Valgimigli (pone.0291061.ref021) 2022; 43 R Mehran (pone.0291061.ref007) 2019; 381 JY Hahn (pone.0291061.ref005) 2019; 321 F Costa (pone.0291061.ref002) 2017; 389 P Vranckx (pone.0291061.ref006) 2018; 392 PC Smits (pone.0291061.ref022) 2021; 144 YJ Lee (pone.0291061.ref024) 2022; 52 R Mehran (pone.0291061.ref018) 2011 F Costa (pone.0291061.ref032) 2023; 44 F Costa (pone.0291061.ref012) 2019; 73 M Valgimigli (pone.0291061.ref004) 2021; 78 S Benenati (pone.0291061.ref030) 2021; 7 BK Koo (pone.0291061.ref034) 2021; 397 SU Khan (pone.0291061.ref028) 2020 S Benenati (pone.0291061.ref031) 2022; 8 H-S Kim (pone.0291061.ref038) 2020; 396 JAC Sterne (pone.0291061.ref014) 2019 M Valgimigli (pone.0291061.ref020) 2022; 80 T Palmerini (pone.0291061.ref033) 2012; 5 T Cuisset (pone.0291061.ref036) HM Garcia-Garcia (pone.0291061.ref017) 2018; 137 S Windecker (pone.0291061.ref003) 2020; 382 H Watanabe (pone.0291061.ref010) 2019; 321
References_xml	– volume: 144 start-page: 1196 year: 2021 ident: pone.0291061.ref022 article-title: Abbreviated Antiplatelet Therapy in Patients at High Bleeding Risk With or Without Oral Anticoagulant Therapy After Coronary Stenting: An Open-Label, Randomized publication-title: Controlled Trial. Circulation – volume: 73 start-page: 741 year: 2019 ident: pone.0291061.ref012 article-title: Dual Antiplatelet Therapy Duration Based on Ischemic and Bleeding Risks After Coronary Stenting publication-title: Journal of the American College of Cardiology doi: 10.1016/j.jacc.2018.11.048 – volume: 15 start-page: E012004 year: 2022 ident: pone.0291061.ref027 article-title: Clopidogrel Monotherapy After 1-Month Dual Antiplatelet Therapy in Percutaneous Coronary Intervention: From the STOPDAPT-2 Total Cohort. Circulation publication-title: Cardiovascular Interventions – year: 2020 ident: pone.0291061.ref028 article-title: Dual Antiplatelet Therapy After Percutaneous Coronary Intervention and Drug-Eluting Stents: A Systematic Review and Network Meta-Analysis publication-title: Circulation – volume: 382 start-page: 1208 year: 2020 ident: pone.0291061.ref003 article-title: Polymer-based or Polymer-free Stents in Patients at High Bleeding Risk. publication-title: New England Journal of Medicine doi: 10.1056/NEJMoa1910021 – volume: 44 start-page: 954 year: 2023 ident: pone.0291061.ref032 article-title: Dual antiplatelet therapy duration after percutaneous coronary intervention in high bleeding risk: a meta-analysis of randomized trials publication-title: Eur Heart J doi: 10.1093/eurheartj/ehac706 – start-page: 366 year: 2019 ident: pone.0291061.ref014 article-title: RoB 2: A revised tool for assessing risk of bias in randomised trials publication-title: The BMJ – volume: 392 start-page: 940 year: 2018 ident: pone.0291061.ref006 article-title: Ticagrelor plus aspirin for 1 month, followed by ticagrelor monotherapy for 23 months vs aspirin plus clopidogrel or ticagrelor for 12 months, followed by aspirin monotherapy for 12 months after implantation of a drug-eluting stent: a multicentre, open-label, randomised superiority trial publication-title: The Lancet doi: 10.1016/S0140-6736(18)31858-0 – year: 2011 ident: pone.0291061.ref018 article-title: Special Report Standardized Bleeding Definitions for Cardiovascular Clinical Trials A Consensus Report From the Bleeding Academic Research Consortium. – volume: 397 start-page: 2487 year: 2021 ident: pone.0291061.ref034 article-title: Aspirin versus clopidogrel for chronic maintenance monotherapy after percutaneous coronary intervention (HOST-EXAM): an investigator-initiated, prospective, randomised, open-label, multicentre trial. publication-title: The Lancet doi: 10.1016/S0140-6736(21)01063-1 – volume: 385 start-page: 1643 year: 2021 ident: pone.0291061.ref019 article-title: Dual Antiplatelet Therapy after PCI in Patients at High Bleeding Risk. publication-title: New England Journal of Medicine doi: 10.1056/NEJMoa2108749 – volume: 398 start-page: 1305 year: 2021 ident: pone.0291061.ref037 article-title: Unguided de-escalation from ticagrelor to clopidogrel in stabilised patients with acute myocardial infarction undergoing percutaneous coronary intervention (TALOS-AMI): an investigator-initiated, open-label, multicentre, non-inferiority, randomised trial. publication-title: The Lancet doi: 10.1016/S0140-6736(21)01445-8 – volume: 42 start-page: 4624 year: 2021 ident: pone.0291061.ref023 article-title: Ticagrelor monotherapy in patients at high bleeding risk undergoing percutaneous coronary intervention: TWILIGHT-HBR publication-title: European Heart Journal doi: 10.1093/eurheartj/ehab702 – volume: 365 start-page: l2222 year: 2019 ident: pone.0291061.ref029 article-title: Duration of dual antiplatelet therapy after percutaneous coronary intervention with drug-eluting stent: systematic review and network meta-analysis publication-title: BMJ doi: 10.1136/bmj.l2222 – volume: 137 start-page: 2635 year: 2018 ident: pone.0291061.ref017 article-title: Standardized End Point Definitions for Coronary Intervention Trials: The Academic Research Consortium-2 publication-title: Consensus Document. Circulation doi: 10.1161/CIRCULATIONAHA.117.029289 – volume: 396 start-page: 1079 year: 2020 ident: pone.0291061.ref038 article-title: Prasugrel-based de-escalation of dual antiplatelet therapy after percutaneous coronary intervention in patients with acute coronary syndrome (HOST-REDUCE-POLYTECH-ACS): an open-label, multicentre, non-inferiority randomised trial. publication-title: The Lancet doi: 10.1016/S0140-6736(20)31791-8 – volume: 115 start-page: 2344 year: 2007 ident: pone.0291061.ref016 article-title: Clinical end points in coronary stent trials: a case for standardized definitions publication-title: Circulation doi: 10.1161/CIRCULATIONAHA.106.685313 – volume: 64 start-page: 401 year: 2011 ident: pone.0291061.ref015 article-title: GRADE guidelines: 3. Rating the quality of evidence publication-title: Journal of Clinical Epidemiology doi: 10.1016/j.jclinepi.2010.07.015 – volume: 78 start-page: 2060 year: 2021 ident: pone.0291061.ref004 article-title: Duration of Dual Antiplatelet Therapy for Patients at High Bleeding Risk Undergoing PCI publication-title: Journal of the American College of Cardiology doi: 10.1016/j.jacc.2021.08.074 – volume: 80 start-page: 766 year: 2022 ident: pone.0291061.ref020 article-title: Impact of Medication Nonadherence in a Clinical Trial of Dual Antiplatelet Therapy publication-title: Journal of the American College of Cardiology doi: 10.1016/j.jacc.2022.04.065 – volume: 76 start-page: 162 year: 2020 ident: pone.0291061.ref011 article-title: Post-Discharge Bleeding and Mortality Following Acute Coronary Syndromes With or Without PCI publication-title: Journal of the American College of Cardiology doi: 10.1016/j.jacc.2020.05.031 – start-page: 34 year: 2018 ident: pone.0291061.ref001 article-title: 2018 Canadian Cardiovascular Society/Canadian Association of Interventional Cardiology Focused Update of the Guidelines for the Use of Antiplatelet Therapy publication-title: Canadian Journal of Cardiology – volume: 321 start-page: 2414 year: 2019 ident: pone.0291061.ref010 article-title: Effect of 1-Month Dual Antiplatelet Therapy Followed by Clopidogrel vs 12-Month Dual Antiplatelet Therapy on Cardiovascular and Bleeding Events in Patients Receiving PCI: The STOPDAPT-2 Randomized Clinical Trial. publication-title: JAMA—Journal of the American Medical Association doi: 10.1001/jama.2019.8145 – volume: 348 start-page: 1329 year: 1996 ident: pone.0291061.ref035 article-title: A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). publication-title: Lancet doi: 10.1016/S0140-6736(96)09457-3 – volume: 140 start-page: 240 year: 2019 ident: pone.0291061.ref013 article-title: Defining High Bleeding Risk in Patients Undergoing Percutaneous Coronary Intervention publication-title: Circulation doi: 10.1161/CIRCULATIONAHA.119.040167 – volume: 389 start-page: 1025 year: 2017 ident: pone.0291061.ref002 article-title: Derivation and validation of the predicting bleeding complications in patients undergoing stent implantation and subsequent dual antiplatelet therapy (PRECISE-DAPT) score: a pooled analysis of individual-patient datasets from clinical trials. publication-title: The Lancet doi: 10.1016/S0140-6736(17)30397-5 – volume: 321 start-page: 2428 year: 2019 ident: pone.0291061.ref005 article-title: Effect of P2Y12 Inhibitor Monotherapy vs Dual Antiplatelet Therapy on Cardiovascular Events in Patients Undergoing Percutaneous Coronary Intervention: The SMART-CHOICE Randomized Clinical Trial publication-title: JAMA doi: 10.1001/jama.2019.8146 – volume: 36 start-page: 91 year: 2021 ident: pone.0291061.ref026 article-title: Details on the effect of very short dual antiplatelet therapy after drug-eluting stent implantation in patients with high bleeding risk: insight from the STOPDAPT-2 trial. publication-title: Cardiovascular intervention and therapeutics doi: 10.1007/s12928-020-00651-9 – volume: 52 start-page: 324 year: 2022 ident: pone.0291061.ref024 article-title: Ticagrelor Monotherapy After 3- publication-title: Month Dual Antiplatelet Therapy in Acute Coronary Syndrome by High Bleeding Risk: The Subanalysis From the TICO Trial. Korean Circulation Journal – volume: 43 start-page: 3100 year: 2022 ident: pone.0291061.ref021 article-title: Duration of antiplatelet therapy after complex percutaneous coronary intervention in patients at high bleeding risk: a MASTER DAPT trial sub-analysis publication-title: European heart journal doi: 10.1093/eurheartj/ehac284 – volume: 323 start-page: 2407 year: 2020 ident: pone.0291061.ref008 article-title: Effect of Ticagrelor Monotherapy vs Ticagrelor With Aspirin on Major Bleeding and Cardiovascular Events in Patients With Acute Coronary Syndrome: The TICO Randomized Clinical Trial publication-title: JAMA doi: 10.1001/jama.2020.7580 – volume: 7 start-page: 407 year: 2022 ident: pone.0291061.ref009 article-title: Comparison of Clopidogrel Monotherapy after 1 to 2 Months of Dual Antiplatelet Therapy with 12 Months of Dual Antiplatelet Therapy in Patients with Acute Coronary Syndrome: The STOPDAPT-2 ACS Randomized Clinical Trial publication-title: JAMA Cardiology doi: 10.1001/jamacardio.2021.5244 – volume: 7 start-page: 86 year: 2021 ident: pone.0291061.ref030 article-title: Very short vs. long dual antiplatelet therapy after second generation drug-eluting stents in 35 785 patients undergoing percutaneous coronary interventions: a meta-analysis of randomized controlled trials publication-title: Eur Heart J Cardiovasc Pharmacother doi: 10.1093/ehjcvp/pvaa001 – ident: pone.0291061.ref036 article-title: Benefit of switching dual antiplatelet therapy after acute coronary syndrome: the TOPIC (timing of platelet inhibition after acute coronary syndrome) randomized study. doi: 10.1093/eurheartj/ehx175 – volume: 140 start-page: 1957 year: 2019 ident: pone.0291061.ref025 article-title: Very Short Dual Antiplatelet Therapy after Drug-Eluting Stent Implantation in Patients with High Bleeding Risk: Insight from the STOPDAPT-2 publication-title: Trial. Circulation doi: 10.1161/CIRCULATIONAHA.119.043613 – volume: 8 start-page: 56 year: 2022 ident: pone.0291061.ref031 article-title: Duration of dual antiplatelet therapy and subsequent monotherapy type in patients undergoing drug-eluting stent implantation: a network meta-analysis publication-title: Eur Heart J Cardiovasc Pharmacother doi: 10.1093/ehjcvp/pvaa127 – volume: 5 start-page: 357 year: 2012 ident: pone.0291061.ref033 article-title: Stent thrombosis with everolimus-eluting stents: meta-analysis of comparative randomized controlled trials publication-title: Circulation Cardiovascular interventions doi: 10.1161/CIRCINTERVENTIONS.111.967083 – volume: 381 start-page: 2032 year: 2019 ident: pone.0291061.ref007 article-title: Ticagrelor with or without Aspirin in High-Risk Patients after PCI publication-title: New England Journal of Medicine doi: 10.1056/NEJMoa1908419
SSID	ssj0053866
Score	2.4669285
Snippet	Introduction Dual antiplatelet therapy (DAPT) following percutaneous coronary intervention (PCI) reduces major adverse cardiovascular events (MACE) and stent... Dual antiplatelet therapy (DAPT) following percutaneous coronary intervention (PCI) reduces major adverse cardiovascular events (MACE) and stent thrombosis.... Introduction Dual antiplatelet therapy (DAPT) following percutaneous coronary intervention (PCI) reduces major adverse cardiovascular events (MACE) and stent...
SourceID	plos doaj pubmedcentral proquest gale crossref
SourceType	Open Website Open Access Repository Aggregation Database Enrichment Source Index Database
StartPage	e0291061
SubjectTerms	Acute coronary syndromes Aggregation Angioplasty Anticoagulants Antiplatelet therapy Bias Bleeding Blood clot Blood platelets Cardiovascular diseases Care and treatment Clinical trials Confidence intervals Consortia Health risks Heart attacks Implants Intervention Ischemia Medicine and Health Sciences Meta-analysis Mortality Patient outcomes Physical Sciences Prevention Research and Analysis Methods Risk assessment Stents Systematic review Thromboembolism Thrombosis
SummonAdditionalLinks	– databaseName: Open Access: DOAJ - Directory of Open Access Journals dbid: DOA link: http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV1Lb9NAEF6hiAMXRHmohlIWhAQc3Npe2xtzK4gKJFQQgaq31T5ppOBYcVKpP4T_y4x3Y2UlpHLgmOw4sWdmZ76RZ74l5KWDpKCVrdKpY1lacqPSBqJgqrRhhXWa24GO4fwzPzubXlw0X3eO-sKeME8P7BV3XNaGS1aWUtumBLQhC6lypcqqYo2y9QCNAPVsiykfg2EX13UYlGM8Pw52OeqWrT3KigbroCgRDXz9Y1SedItlH0HOuGFyJwOd3iN3A3SkJ_6W98gt294ne2Fz9vR1YJB-84D8nl0CqqY4ZkVBc_NuAYgSDET9tNU1rHjD0-GIcNrZld4ASrTLTU81chrI1TWd77RDwgeKzMZULXy6o9iTTgMra_-WzkZGaOqnYeCPDf1l1zKVgffkIflx-uH7-49pOH8h1TXP1ql2rlRFZSU8eOUkYDGnDMQDY5pCFpUBsJgVFs_uqBvnFEClSlacS6lBwkrFHpFJCxrfJxQ9AYo75jJpylzmkiHSNC7XdaVLzRLCtsYQOpCT4xkZCzG8ceNQpHglCzShCCZMSDpe1Xlyjhvk36GdR1mk1h6-AIcTweHETQ6XkGfoJcLPqY4BQpxAWmmm-No5IS8GCaTXaLF_56fc9L349OX8H4Rm3yKhV0HILUEdWoaZCXgmpO2KJA8iSQgSOlreR5_eaqUXyFvYcJxEhiu3fv735efjMv4o9uQN7ggyNWYAgPAJmUb7I1JwvNLOLwcOc2QIYVCLPP4fJnlC7hSAPX3r3wGZrFcb-5Tc1lfreb86HCLDH2RXcEU priority: 102 providerName: Directory of Open Access Journals – databaseName: Biological Science Database dbid: M7P link: http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV1Lb9QwELZg4cAFKA81UMAgJOCQNonz2HBBBVGBhErFQtVb5Ge70pKEZBepP4T_y4zjhFpCgMRx48lGsccz38Qz3xDy1IBTkEJn4dywKEwLJcISrGAopGKJNrLQlo7h-ENxeDg_OSmP3Ae33qVVjjbRGmrVSPxGvodEa2WBpZOv2m8hdo3C01XXQuMyuYIsCcym7h2Nlhj2cp67cjlWxHtudXbbpta7UVJiNOS5I8vaP9nmWbtqeg94-mmTF_zQwY3_fYOb5LpDoHR_UJktcknXt8iW2-M9fe6IqF_cJj8WZwDOKVZrUViAZbsCYArrTIeirXMYGfSH2k7jtNWd3ADY1M2mpxKpEXh3TpcXsirhB0WCZCpWg9ekmNpOHblr_5IuJmJpOhTVwIMV_arXPOSOPuUO-XLw9vObd6Fr4xDKvIjWoTQmFUmmOcxcZjhAOiMUmBWlyoQnmQLMGSUaW4DkpTECEFfGs6LgXIKE5oLdJbMalmybUFQoiBGZibhKYx5zhoBVmVjmmUwlCwgbV7OSjuMcW22sKntwV0CsM0xyhTpQOR0ISDjd1Q4cH3-Rf42KMskiQ7e90HSnldvwVZqrgrM05VKXKaBknnARC5FmGSuFznlAHqGaVUO562Rnqn3wTuUcT68D8sRKIEtHjWlAp3zT99X7j8f_ILT45Ak9c0KmgemQ3JVewDsh-5cnueNJgq2R3vA2bopxVvrql07DnaPW_3748TSMf4qpfVYdQSZHRwKRQEDm3gbzJtgfqZdnlgodiUYYhDT3_vz0--RaAuB0yA3cIbN1t9EPyFX5fb3su4fWaPwErCB-NQ priority: 102 providerName: ProQuest
Title	Short dual antiplatelet therapy duration after percutaneous coronary intervention in high bleeding risk patients: Systematic review and meta-analysis
URI	https://www.proquest.com/docview/2859970579 https://www.proquest.com/docview/2860400835 https://pubmed.ncbi.nlm.nih.gov/PMC10473507 https://doaj.org/article/46d7a344ace94193a2ab1bb45539be6a http://dx.doi.org/10.1371/journal.pone.0291061
Volume	18
WOSCitedRecordID	wos001066578500007&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D
hasFullText	1
inHoldings	1
isFullTextHit
isPrint
journalDatabaseRights	– providerCode: PRVAON databaseName: DOAJ Directory of Open Access Journals customDbUrl: eissn: 1932-6203 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0053866 issn: 1932-6203 databaseCode: DOA dateStart: 20060101 isFulltext: true titleUrlDefault: https://www.doaj.org/ providerName: Directory of Open Access Journals – providerCode: PRVHPJ databaseName: ROAD: Directory of Open Access Scholarly Resources customDbUrl: eissn: 1932-6203 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0053866 issn: 1932-6203 databaseCode: M~E dateStart: 20060101 isFulltext: true titleUrlDefault: https://road.issn.org providerName: ISSN International Centre – providerCode: PRVPQU databaseName: Advanced Technologies & Aerospace Database customDbUrl: eissn: 1932-6203 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0053866 issn: 1932-6203 databaseCode: P5Z dateStart: 20061201 isFulltext: true titleUrlDefault: https://search.proquest.com/hightechjournals providerName: ProQuest – providerCode: PRVPQU databaseName: Agricultural Science Database customDbUrl: eissn: 1932-6203 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0053866 issn: 1932-6203 databaseCode: M0K dateStart: 20061201 isFulltext: true titleUrlDefault: https://search.proquest.com/agriculturejournals providerName: ProQuest – providerCode: PRVPQU databaseName: Biological Science Database customDbUrl: eissn: 1932-6203 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0053866 issn: 1932-6203 databaseCode: M7P dateStart: 20061201 isFulltext: true titleUrlDefault: http://search.proquest.com/biologicalscijournals providerName: ProQuest – providerCode: PRVPQU databaseName: Engineering Database customDbUrl: eissn: 1932-6203 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0053866 issn: 1932-6203 databaseCode: M7S dateStart: 20061201 isFulltext: true titleUrlDefault: http://search.proquest.com providerName: ProQuest – providerCode: PRVPQU databaseName: Environmental Science Database customDbUrl: eissn: 1932-6203 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0053866 issn: 1932-6203 databaseCode: PATMY dateStart: 20061201 isFulltext: true titleUrlDefault: http://search.proquest.com/environmentalscience providerName: ProQuest – providerCode: PRVPQU databaseName: Materials Science Database customDbUrl: eissn: 1932-6203 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0053866 issn: 1932-6203 databaseCode: KB. dateStart: 20061201 isFulltext: true titleUrlDefault: http://search.proquest.com/materialsscijournals providerName: ProQuest – providerCode: PRVPQU databaseName: Nursing & Allied Health Database customDbUrl: eissn: 1932-6203 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0053866 issn: 1932-6203 databaseCode: 7RV dateStart: 20061201 isFulltext: true titleUrlDefault: https://search.proquest.com/nahs providerName: ProQuest – providerCode: PRVPQU databaseName: ProQuest Central customDbUrl: eissn: 1932-6203 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0053866 issn: 1932-6203 databaseCode: BENPR dateStart: 20061201 isFulltext: true titleUrlDefault: https://www.proquest.com/central providerName: ProQuest – providerCode: PRVPQU databaseName: ProQuest_Health & Medical Collection customDbUrl: eissn: 1932-6203 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0053866 issn: 1932-6203 databaseCode: 7X7 dateStart: 20061201 isFulltext: true titleUrlDefault: https://search.proquest.com/healthcomplete providerName: ProQuest – providerCode: PRVPQU databaseName: Public Health Database customDbUrl: eissn: 1932-6203 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0053866 issn: 1932-6203 databaseCode: 8C1 dateStart: 20061201 isFulltext: true titleUrlDefault: https://search.proquest.com/publichealth providerName: ProQuest – providerCode: PRVPQU databaseName: Publicly Available Content Database customDbUrl: eissn: 1932-6203 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0053866 issn: 1932-6203 databaseCode: PIMPY dateStart: 20061201 isFulltext: true titleUrlDefault: http://search.proquest.com/publiccontent providerName: ProQuest – providerCode: PRVATS databaseName: Public Library of Science (PLoS) Journals Open Access customDbUrl: eissn: 1932-6203 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0053866 issn: 1932-6203 databaseCode: FPL dateStart: 20060101 isFulltext: true titleUrlDefault: http://www.plos.org/publications/ providerName: Public Library of Science
link	http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwlV3db9MwELdYxwMvwPjQCqMYhAQ8pCRxEie8rdMqpm0laqHqeIlsx2aVSls1LdL-EP5f7hI3LIgJeDmp9blNz_fl-u5nQl4ZCApK6tCJDXOdgOfSScALOlLlzNdGcV3CMYzP-GAQTyZJ-muj-NsJPuPeOyvT7nIx113XT3APs0N2fRZFWMLVT8-2nhdsN4pse9xNMxvhp0Tpr31xazlbFI1Es1kmeS3u9O_97xPfJ3dthkkPK5XYI7f0_AHZszZc0DcWaPrtQ_JjdAnJN8VuLAoCni5nkHjCOtKqKesKRir9oOVN4nSpV2oDyaRebAqqEPpArK7o9FrVJLygCIBM5ayKihRL16kFby3e01ENHE2rphn44px-02vhCAuP8oh87h9_Ovrg2GsaHBVxd-0oYwLph1qApEIjIGUzMge3keeJL_wwh5zS9TVe8RElxkjIqEIRci6EAg4tJHtMWnMQ1T6hqDCwB2TGFXngCU8wTEhz46koVIFibcK2q5cpi2GOV2nMsvJgjsNephJyhrLPrOzbxKlnLSsMj7_w91Axal5E4C7fgEXOrEFnQZRzwYJAKJ0EkAULX0hPyiAMWSJ1JNrkOapVVrWz1n4kO4Tok8R4Ot0mL0sOROGYY5nPV7Epiuzk4_gfmEbDBtNry2QWIA4lbGsF_CZE92pwHjQ4wZeoxvA-GsFWKkWG8IYJx4ZlmLk1jD8Pv6iH8UOxdK9UR-CJMFBApt8mccOgGgJujsynlyXUOQKJMNiyPLn5wZ6SOz4knlXd3wFprVcb_YzcVt_X02LVITt8OEY64SWNgcZHXofs9o4H6bBT_gfTKd0I0NNeF-i5e4qUpyUdAU3DLzAjPTlPL34Cw3545A
linkProvider	Public Library of Science
linkToHtml	http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMw1V1Lb9NAEF6VgAQXoDzUQKELAgEHt7bXjxgJofKoGjUE1JSoN7PPNlKITZyA8kP4G_xGZuy1qSUEXHrgmOzYVibfzM54Z74h5JGBTUEKHTo9w1wniJVwEvCCjpCK-drIWJd0DONBPBz2jo-TD2vkR90Lg2WVtU8sHbXKJL4j30GitSTG1smX-RcHp0bh6Wo9QqOCxYFefYOUrXjRfwP_72Pf33t79HrfsVMFHBnF7sKRxgTCDzXXSoaGQ4RhhAKUK5X43A8VhECur3EiRZQYIyAACHkYx5xLkNBcMLjvBXIR_LiHJWTx4bj2_OA7osi257HY27Fo2M6zmd52Qd6NvNb2V04JaPaCTj7Nilag2y7TPLPv7V373zR2nVy1ETbdrUxinazp2Q2ybn1YQZ9aou1nN8n30SkkHxS70SgAbJJPIfAGHNOqKW0FK5V90HKSOs31XC4hmNbZsqASqR_4fEUnZ6pG4QNFAmgqplVUQLF0n1ry2uI5HTXE2bRqGoIHK_pZL7jDLT3MLfLxXNRzm3RmAJENQtFgIAdmxuUq8LjHGQbkyngyCmUgWZewGj2ptBzuOEpkmpYHkzHkcpWSU8RcajHXJU5zVV5xmPxF_hUCs5FFBvLyi2x-klqHlgaRijkLAi51EkAWwH0uPCGCMGSJ0BHvki2EdVq18zZ-NN2F3Tfp4el8lzwsJZCFZIZlTid8WRRp__34H4RGhy2hJ1bIZKAOyW1rCfwmZDdrSW62JMGXytbyBhphrZUi_WVDcGVtZb9fftAs402xdLGEI8hEuFFCptMlvZZBtxTcXplNTkuqdyRSYZCy3fnz07fI5f2jd4N00B8e3CVXfAjEqzrITdJZzJf6Hrkkvy4mxfx-6bAo-XTe9v4TtAHeuQ
linkToPdf	http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMw1V1Lb9NAEF6VgBAXoDzUQKELAgEHN4nXjxgJodISEbUKFSlVb8s-20ghNnECyg_hz_DrmLHXppYQcOmBY7JjW5l8MzvjnfmGkCcWNgUlTej1Let6Qayll4AX9KTSzDdWxaagYzg-iEej_slJcrhGflS9MFhWWfnEwlHrVOE78g4SrSUxtk52rCuLONwbvM6-eDhBCk9aq3EaJUT2zeobpG_5q-Ee_NdPfX_w9mj3necmDHgqirsLT1kbSD80wmgVWgHRhpUaEK914gs_1BAOdX2D0ymixFoJwUAowjgWQoGEEZLBfS-RyzEDFGOX-m5dXgJ-JIpcqx6Lex2HjO0snZntrp9gJtbYCouJAfW-0Mqmad4Iepslm-f2wMGN_1l7N8l1F3nTndJU1smamd0i68635fS5I-B-cZt8H59BUkKxS40C8CbZFAJywDctm9VWsFLaDS0mrNPMzNUSgmyTLnOqkBJCzFd0cq6aFD5QJIamclpGCxRL-qkjtc1f0nFNqE3LZiJ4sKafzUJ4wtHG3CEfL0Q9d0lrBnDZIBQNCXJjZrtCBz3REwwDdW17KgpVoFibsApJXDludxwxMuXFgWUMOV6pZI744w5_beLVV2Ult8lf5N8gSGtZZCYvvkjnp9w5Oh5EOhYsCIQySQDZgfCF7EkZhCFLpIlEm2whxHnZ5lv7V74Du3LSx1P7NnlcSCA7yQyReiqWec6H74__QWj8oSH0zAnZFNShhGs5gd-ErGcNyc2GJPhY1VjeQIOstJLzX_YEV1YW9_vlR_Uy3hRLGgs4gkyEGyhkQG3Sbxh3Q8HNldnkrKCAR4IVBqncvT8_fYtcBTPnB8PR_n1yzYf4vCyP3CStxXxpHpAr6utiks8fFr6Lkk8Xbe4_Ad0c5xQ
openUrl	ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Short+dual+antiplatelet+therapy+duration+after+percutaneous+coronary+intervention+in+high+bleeding+risk+patients%3A+Systematic+review+and+meta-analysis&rft.jtitle=PloS+one&rft.au=Bainey%2C+Kevin&rft.au=Marquis-Gravel%2C+Guillaume&rft.au=MacDonald%2C+Blair&rft.au=Bewick%2C+David&rft.date=2023-09-01&rft.pub=Public+Library+of+Science&rft.eissn=1932-6203&rft.volume=18&rft.issue=9&rft_id=info:doi/10.1371%2Fjournal.pone.0291061&rft.externalDocID=2859970579
thumbnail_l	http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1932-6203&client=summon
thumbnail_m	http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1932-6203&client=summon
thumbnail_s	http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1932-6203&client=summon